PMX 205 (Trifluoroacetate)

OC(C(F)(F)F)=O.O=C([C@H](NC([C@@]1([H])N(CCC1)C([C@](NC(CCC2=CC=CC=C2)=O)([H])CCCNC([C@H](CCCNC(N)=N)NC3=O)=O)=O)=O)CC4CCCCC4)N[C@@]3([H])CC5=CNC6=CC=CC=C56

[1]Kosni NN, et al. Expression of complement C5a receptor and the viability of 4T1 tumor cells following agonist-antagonist treatment. J Cancer Res Ther. 2016 Apr-Jun;12(2):590-6.|[2]Woodruff TM, et al. The complement factor C5a contributes to pathology in a rat model of amyotrophic lateral sclerosis. J Immunol. 2008 Dec 15;181(12):8727-34.|[3]Fonseca MI, et al. Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer's disease. J Immunol. 2009 Jul 15;183(2):1375-83.|[4]Toutonji A, et al. Mass cytometric analysis of the immune cell landscape after traumatic brain injury elucidates the role of complement and complement receptors in neurologic outcomes[J]. Acta Neuropathologica Communications, 2023, 11(1): 92.Adv Sci (Weinh). 2024 Jun 5:e2400819.|Cell Death Dis. 2024 Oct 5;15(10):729.|Int J Cancer. 2023 Jul 1;153(1):224-237.|La Trobe University. 2022 Jan.|Cell Mol Neurobiol. 2022 Aug 25.|Cell Rep. 2023 Mar 15;42(3):112240.|Theranostics. 2019 Oct 12;9(25):7566-7582.